. 2021 Dec;99(12):1783-1795.

doi: 10.1007/s00109-021-02138-3. Epub 2021 Oct 9.

JAK2 regulates paclitaxel resistance in triple negative breast cancers

Jongmin Han^#¹, Jihui Yun^#^{2

3}, Mingji Quan¹, Wonyoung Kang^{4

5}, Ji-Gwang Jung⁶, Woohang Heo¹, Songbin Li¹, Kyu Jin Lee¹, Hye-Youn Son⁷, Ju Hee Kim⁷, Jaeyong Choi^{2

3}, Dong-Young Noh^{6

8

9}, Deukchae Na⁵, Han Suk Ryu¹⁰, Charles Lee^{4

5

11}, Jong-Il Kim^{12

13

14

15}, Hyeong-Gon Moon^{16

17

18}

Affiliations

¹ Interdisciplinary Graduate Program in Cancer Biology, Seoul National University College of Medicine, Seoul, Korea.
² Medical Research Center, Genomic Medicine Institute, Seoul National University, Seoul, Korea.
³ Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
⁴ The Jackson Laboratory of Genomic Medicine, Farmington, CT, USA.
⁵ Department of Life Sciences, Ewha Womans University, Seoul, Korea.
⁶ Department of Surgery, Seoul National University Hospital, Seoul, Korea.
⁷ Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea.
⁸ Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
⁹ Cancer Research Institute, Seoul National University, Seoul, Korea.
¹⁰ Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
¹¹ Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
¹² Medical Research Center, Genomic Medicine Institute, Seoul National University, Seoul, Korea. jongil@snu.ac.kr.
¹³ Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. jongil@snu.ac.kr.
¹⁴ Cancer Research Institute, Seoul National University, Seoul, Korea. jongil@snu.ac.kr.
¹⁵ Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, Korea. jongil@snu.ac.kr.
¹⁶ Department of Surgery, Seoul National University Hospital, Seoul, Korea. moonhg74@snu.ac.kr.
¹⁷ Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. moonhg74@snu.ac.kr.
¹⁸ Cancer Research Institute, Seoul National University, Seoul, Korea. moonhg74@snu.ac.kr.

^# Contributed equally.

PMID: 34626199
DOI: 10.1007/s00109-021-02138-3

JAK2 regulates paclitaxel resistance in triple negative breast cancers

Jongmin Han et al. J Mol Med (Berl). 2021 Dec.

. 2021 Dec;99(12):1783-1795.

doi: 10.1007/s00109-021-02138-3. Epub 2021 Oct 9.

Authors

Affiliations

¹ Interdisciplinary Graduate Program in Cancer Biology, Seoul National University College of Medicine, Seoul, Korea.
² Medical Research Center, Genomic Medicine Institute, Seoul National University, Seoul, Korea.
³ Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
⁴ The Jackson Laboratory of Genomic Medicine, Farmington, CT, USA.
⁵ Department of Life Sciences, Ewha Womans University, Seoul, Korea.
⁶ Department of Surgery, Seoul National University Hospital, Seoul, Korea.
⁷ Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea.
⁸ Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
⁹ Cancer Research Institute, Seoul National University, Seoul, Korea.
¹⁰ Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
¹¹ Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
¹² Medical Research Center, Genomic Medicine Institute, Seoul National University, Seoul, Korea. jongil@snu.ac.kr.
¹³ Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. jongil@snu.ac.kr.
¹⁴ Cancer Research Institute, Seoul National University, Seoul, Korea. jongil@snu.ac.kr.
¹⁵ Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, Korea. jongil@snu.ac.kr.
¹⁶ Department of Surgery, Seoul National University Hospital, Seoul, Korea. moonhg74@snu.ac.kr.
¹⁷ Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. moonhg74@snu.ac.kr.
¹⁸ Cancer Research Institute, Seoul National University, Seoul, Korea. moonhg74@snu.ac.kr.

^# Contributed equally.

PMID: 34626199
DOI: 10.1007/s00109-021-02138-3

Abstract

We investigated the molecular mechanisms of paclitaxel resistance in TNBC using seven patient-derived xenograft (PDX) models and TNBC cell lines. Among the seven PDX models, four models showed resistance to paclitaxel. Dysregulation of JAK/STAT pathways and JAK2 copy number gains were observed in the four paclitaxel-resistant PDX tumors. In TNBC cell lines, silencing the JAK2 gene showed a significant but mild synergistic effect when combined with paclitaxel in vitro. However, JAK1/2 inhibitor treatment resulted in restoration of paclitaxel sensitivity in two out of four paclitaxel-resistant PDX models and JAK1/2 inhibitor alone significantly suppressed the tumor growth in one out of the two remaining PDX models. Transcriptome data derived from the murine microenvironmental cells revealed an enrichment of genes involved in the cell cycle processes among the four paclitaxel-resistant PDX tumors. Histologic examination of those PDX tumor tissues showed increased Ki67-positive fibroblasts in the tumor microenvironment. Among the four different cancer-associated fibroblast (CAF) subtypes, cycling CAF exhibiting features of active cell cycle was enriched in the paclitaxel-resistant PDX tumors. Additionally, fibroblasts treated with the conditioned media from the JAK2-silenced breast cancer cells showed downregulation of cell cycle-related genes. Our data suggest that the JAK2 gene may play a critical role in determining responses of TNBC to paclitaxel by modulating the intrinsic susceptibility of cancer cells against paclitaxel and also by eliciting functional transitions of CAF subtypes in the tumor microenvironment. KEY MESSAGES : We investigated the molecular mechanisms of paclitaxel resistance in TNBC. JAK2 signaling was associated with paclitaxel resistance in TNBC PDX models. Paclitaxel-resistant PDX tumors were enriched with microenvironment cCAF subpopulation. JAK2 regulated paclitaxel-resistant CAF phenotype transition.

Keywords: Breast cancer; Fibroblast; JAK2; Microenvironment; Paclitaxel; Triple negative breast cancer.

PubMed Disclaimer

Cited by

Potential Perturbations of Critical Cancer-regulatory Genes in Triple-Negative Breast Cancer Cells Within the Humanized Microenvironment of Patient-derived Xenograft Models.
Her Y, Yun J, Son HY, Heo W, Kim JI, Moon HG. Her Y, et al. J Breast Cancer. 2024 Feb;27(1):37-53. doi: 10.4048/jbc.2023.0177. Epub 2024 Jan 15. J Breast Cancer. 2024. PMID: 38233337 Free PMC article.
AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells.
Li S, Lee W, Heo W, Son HY, Her Y, Kim JI, Moon HG. Li S, et al. J Breast Cancer. 2023 Feb;26(1):60-76. doi: 10.4048/jbc.2023.26.e1. Epub 2022 Dec 16. J Breast Cancer. 2023. PMID: 36762781 Free PMC article.
Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15.
Nishi H, Ono M, Ohno S, Yamanaka Z, Sasaki T, Ohyashiki K, Ohyashiki JH, Kuroda M. Nishi H, et al. Gynecol Oncol Rep. 2023 Jan 21;45:101138. doi: 10.1016/j.gore.2023.101138. eCollection 2023 Feb. Gynecol Oncol Rep. 2023. PMID: 36714373 Free PMC article.
A tubulin binding molecule drives differentiation of acute myeloid leukemia cells.
Jackson TR, Vuorinen A, Josa-Culleré L, Madden KS, Conole D, Cogswell TJ, Wilkinson IVL, Kettyle LM, Zhang D, O'Mahony A, Gracias D, McCall L, Westwood R, Terstappen GC, Davies SG, Tate EW, Wynne GM, Vyas P, Russell AJ, Milne TA. Jackson TR, et al. iScience. 2022 Jul 19;25(8):104787. doi: 10.1016/j.isci.2022.104787. eCollection 2022 Aug 19. iScience. 2022. PMID: 35992086 Free PMC article.
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens.
Srivastava N, Usmani SS, Subbarayan R, Saini R, Pandey PK. Srivastava N, et al. Front Oncol. 2023 Jul 10;13:1199105. doi: 10.3389/fonc.2023.1199105. eCollection 2023. Front Oncol. 2023. PMID: 37492478 Free PMC article. Review.

See all "Cited by" articles

References

1. Jung KW, Won YJ, Kong HJ, Lee ES (2018) Community of population-based regional cancer R. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res Treat 50(2):303–16
1. Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW et al (2018) Basic findings regarding breast cancer in korea in 2015: data from a Breast Cancer Registry. J Breast Cancer 21(1):1–10 - PubMed - PMC
1. Han J, Lee HB, Lee ES, Kang YJ, Kim Y, Choi J et al (2017) The treatment outcomes and the use of adjuvant therapies in breast cancer patients with severe co-morbidities. PLoS One 12(3):e0173721
1. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714–726 - PubMed
1. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

JAK2 regulates paclitaxel resistance in triple negative breast cancers

Affiliations

JAK2 regulates paclitaxel resistance in triple negative breast cancers

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous